Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1997 3
1998 1
1999 3
2000 3
2001 4
2002 2
2003 11
2004 10
2005 3
2006 10
2007 5
2008 5
2009 8
2010 9
2011 11
2012 8
2013 9
2014 12
2015 22
2016 17
2017 16
2018 29
2019 18
2020 26
2021 38
2022 27
2023 36
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

331 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for J. steve well and
Your search for J. Steve Welstand retrieved no results
Consensus statement on concussion in sport: the 6th International Conference on Concussion in Sport-Amsterdam, October 2022.
Patricios JS, Schneider KJ, Dvorak J, Ahmed OH, Blauwet C, Cantu RC, Davis GA, Echemendia RJ, Makdissi M, McNamee M, Broglio S, Emery CA, Feddermann-Demont N, Fuller GW, Giza CC, Guskiewicz KM, Hainline B, Iverson GL, Kutcher JS, Leddy JJ, Maddocks D, Manley G, McCrea M, Purcell LK, Putukian M, Sato H, Tuominen MP, Turner M, Yeates KO, Herring SA, Meeuwisse W. Patricios JS, et al. Br J Sports Med. 2023 Jun;57(11):695-711. doi: 10.1136/bjsports-2023-106898. Br J Sports Med. 2023. PMID: 37316210
Apart from this consensus statement, the conference process yielded revised tools including the Concussion Recognition Tool-6 (CRT6) and Sport Concussion Assessment Tool-6 (SCAT6, Child SCAT6), as well as a new tool, the Sport Concussion Office Assessment Tool-6 (SCOAT6, C …
Apart from this consensus statement, the conference process yielded revised tools including the Concussion Recognition Tool-6 (CRT6) and Spo …
Cognitive behavioral therapy for primary care depression and anxiety: a secondary meta-analytic review using robust variance estimation in meta-regression.
Zhang A, Borhneimer LA, Weaver A, Franklin C, Hai AH, Guz S, Shen L. Zhang A, et al. J Behav Med. 2019 Dec;42(6):1117-1141. doi: 10.1007/s10865-019-00046-z. Epub 2019 Apr 19. J Behav Med. 2019. PMID: 31004323 Free article. Review.
Cognitive-behavioral therapy (CBT) is well supported for treating depressive and anxiety disorders. Trials of CBT for anxiety and depression in primary care have increased over the past decade, yet only one meta-analysis, published in 2015, examined this topic and the scop …
Cognitive-behavioral therapy (CBT) is well supported for treating depressive and anxiety disorders. Trials of CBT for anxiety and dep …
Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
Carroll A, Dyck PJ, de Carvalho M, Kennerson M, Reilly MM, Kiernan MC, Vucic S. Carroll A, et al. J Neurol Neurosurg Psychiatry. 2022 Jun;93(6):668-678. doi: 10.1136/jnnp-2021-327909. Epub 2022 Mar 7. J Neurol Neurosurg Psychiatry. 2022. PMID: 35256455 Free PMC article. Review.
Additionally, TTR gene silencing medications, patisiran and inotersen, have resulted in up to 80% reduction in TTR production, leading to stabilisation or slight improvement of peripheral neuropathy and cardiac dysfunction, as well as improvement in quality of life and fun …
Additionally, TTR gene silencing medications, patisiran and inotersen, have resulted in up to 80% reduction in TTR production, leading to st …
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA. Jones S, et al. J Clin Oncol. 2009 Mar 10;27(8):1177-83. doi: 10.1200/JCO.2008.18.4028. Epub 2009 Feb 9. J Clin Oncol. 2009. PMID: 19204201 Clinical Trial.
We now report 7-year results for DFS and overall survival (OS) as well as the impact of age, hormone receptor status, and HER2 status on outcome and toxicity. ...Baseline characteristics in the two age subgroups were generally well matched, except that older women t …
We now report 7-year results for DFS and overall survival (OS) as well as the impact of age, hormone receptor status, and HER2 status …
Exercise for reducing fear of falling in older people living in the community.
Kendrick D, Kumar A, Carpenter H, Zijlstra GA, Skelton DA, Cook JR, Stevens Z, Belcher CM, Haworth D, Gawler SJ, Gage H, Masud T, Bowling A, Pearl M, Morris RW, Iliffe S, Delbaere K. Kendrick D, et al. Cochrane Database Syst Rev. 2014 Nov 28;2014(11):CD009848. doi: 10.1002/14651858.CD009848.pub2. Cochrane Database Syst Rev. 2014. PMID: 25432016 Free PMC article. Review.
There is insufficient evidence to determine whether exercise interventions reduce fear of falling beyond the end of the intervention or their effect on other outcomes. Although further evidence from well-designed randomised trials is required, priority should be given to e …
There is insufficient evidence to determine whether exercise interventions reduce fear of falling beyond the end of the intervention or thei …
Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures.
Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M, Rosenfeld WE, Sperling MR, Mizne S, Kamin M. Chung SS, et al. Neurology. 2020 Jun 2;94(22):e2311-e2322. doi: 10.1212/WNL.0000000000009530. Epub 2020 May 14. Neurology. 2020. PMID: 32409485 Free PMC article. Clinical Trial.
CONCLUSION: Adjunctive treatment with cenobamate 200 mg/d significantly improved seizure control in adults with uncontrolled focal seizures and was well tolerated. CLINICALTRIALSGOV IDENTIFIER: NCT01397968. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence t …
CONCLUSION: Adjunctive treatment with cenobamate 200 mg/d significantly improved seizure control in adults with uncontrolled focal seizures …
Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy.
Newman NJ, Yu-Wai-Man P, Subramanian PS, Moster ML, Wang AG, Donahue SP, Leroy BP, Carelli V, Biousse V, Vignal-Clermont C, Sergott RC, Sadun AA, Rebolleda Fernández G, Chwalisz BK, Banik R, Bazin F, Roux M, Cox ED, Taiel M, Sahel JA; LHON REFLECT Study Group. Newman NJ, et al. Brain. 2023 Apr 19;146(4):1328-1341. doi: 10.1093/brain/awac421. Brain. 2023. PMID: 36350566 Free PMC article. Clinical Trial.
The proportion of patients with one or both eyes on-chart at 1.5 years was 85.4% and 72.0% for bilaterally and unilaterally treated patients, respectively. The gene therapy was well tolerated, with no systemic issues. Intraocular inflammation, which was mostly mild and …
The proportion of patients with one or both eyes on-chart at 1.5 years was 85.4% and 72.0% for bilaterally and unilaterally treated patients …
JAK inhibitors for asthma.
Georas SN, Donohue P, Connolly M, Wechsler ME. Georas SN, et al. J Allergy Clin Immunol. 2021 Oct;148(4):953-963. doi: 10.1016/j.jaci.2021.08.013. J Allergy Clin Immunol. 2021. PMID: 34625142 Free PMC article. Review.
Here, we review the rationale for use of JAK inhibitors in different asthma endotypes as well as the preclinical and early clinical evidence supporting such use. ...
Here, we review the rationale for use of JAK inhibitors in different asthma endotypes as well as the preclinical and early clinical e …
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L. Jones SE, et al. J Clin Oncol. 2006 Dec 1;24(34):5381-7. doi: 10.1200/JCO.2006.06.5391. J Clin Oncol. 2006. PMID: 17135639 Clinical Trial.
Radiation therapy (as indicated) and tamoxifen, for patients with hormone receptor-positive disease, were administered after completion of chemotherapy. RESULTS: Both treatment groups (TC and AC) were well balanced with respect to major prognostic factors. Patients were ob …
Radiation therapy (as indicated) and tamoxifen, for patients with hormone receptor-positive disease, were administered after completion of c …
331 results